HumacyteHUMA
About: Humacyte Inc is developing a disruptive biotechnology platform to deliver universally implantable bioengineered human tissues and organs designed to improve the lives of patients and transform the practice of medicine. It develops and manufactures acellular tissues to treat a wide range of diseases, injuries, and chronic conditions.
Employees: 185
Fund manager confidence
Based on 2024 Q2 SEC filings by fund managers ($100M+ AUM)
213% more repeat investments, than reductions
Existing positions increased: 50 | Existing positions reduced: 16
156% more first-time investments, than exits
New positions opened: 46 | Existing positions closed: 18
106% more capital invested
Capital invested by funds: $72.9M [Q1] → $150M (+$76.9M) [Q2]
29% more funds holding
Funds holding: 95 [Q1] → 123 (+28) [Q2]
6.17% more ownership
Funds ownership: 20.04% [Q1] → 26.2% (+6.17%) [Q2]
44% less call options, than puts
Call options by funds: $1.55M | Put options by funds: $2.79M
100% less funds holding in top 10
Funds holding in top 10: 2 [Q1] → 0 (-2) [Q2]
Research analyst outlook
7 Wall Street Analysts provided 1 year price targets over the past 3 months
7 analyst ratings
Benchmark Bruce Jackson 42% 1-year accuracy 20 / 48 met price target | 209%upside $15 | Buy Reiterated | 10 Oct 2024 |
EF Hutton Jason Kolbert 39% 1-year accuracy 21 / 54 met price target | 414%upside $25 | Buy Maintained | 1 Oct 2024 |
Cantor Fitzgerald Kristen Kluska 60% 1-year accuracy 55 / 91 met price target | 167%upside $13 | Overweight Reiterated | 20 Sept 2024 |
EF Hutton Jason Kolbert 39% 1-year accuracy 21 / 54 met price target | 414%upside $25 | Buy Initiated | 9 Sept 2024 |
Benchmark Bruce Jackson 42% 1-year accuracy 20 / 48 met price target | 209%upside $15 | Buy Reiterated | 5 Sept 2024 |
Financial journalist opinion
Based on 7 articles about HUMA published over the past 30 days